Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones.

Manhattan Associates said it sees FY2025 adjusted earnings of $4.45 to $4.55 per share, versus market estimates of $4.91 per ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Europe small molecule API market was valued at $43.5 billion in 2022 and will grow by 7.4% annually over 2022-2032, driven by the increasing incidences of diseases, the development of high-potency ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 119 tables and 84 figures, this 187-page report ?Global Small Molecule API Market 2022-2032 by Source (Synthetic, ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...